5-ASAs in Crohn's Disease: Time to Stop the Salicylate?

Sailish Honap^{1

2}, Esha Sharma¹, Mark A Samaan³

Affiliations

¹ IBD Centre, St Thomas' Hospital, NHS Foundation Trust, Westminster Bridge Road, Guy's and St Thomas', London, SE1 7EH, UK.
² School of Immunology and Microbial Sciences, King's College London, London, UK.
³ IBD Centre, St Thomas' Hospital, NHS Foundation Trust, Westminster Bridge Road, Guy's and St Thomas', London, SE1 7EH, UK. mark.samaan@gstt.nhs.uk.

Editorial

Sailish Honap et al. Dig Dis Sci. 2022 Jul.

. 2022 Jul;67(7):2699-2700.

doi: 10.1007/s10620-021-07304-8. Epub 2021 Nov 19.

Sailish Honap^{1

2}, Esha Sharma¹, Mark A Samaan³

¹ IBD Centre, St Thomas' Hospital, NHS Foundation Trust, Westminster Bridge Road, Guy's and St Thomas', London, SE1 7EH, UK.
² School of Immunology and Microbial Sciences, King's College London, London, UK.
³ IBD Centre, St Thomas' Hospital, NHS Foundation Trust, Westminster Bridge Road, Guy's and St Thomas', London, SE1 7EH, UK. mark.samaan@gstt.nhs.uk.

No abstract available

Comment on

No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
Picetti D, Kim J, Zhu W, Sandborn WJ, Jairath V, Singh S. Picetti D, et al. Dig Dis Sci. 2022 Jul;67(7):3115-3123. doi: 10.1007/s10620-021-07301-x. Epub 2021 Nov 19. Dig Dis Sci. 2022. PMID: 34797442 Free PMC article.

1. Lim W-C, Wang Y, MacDonald JK, et al. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database of Systematic Reviews [Internet]. 2016 [cited 2021 Sep 26];(7). Available from: https://www.cochranelibrary.com/cdsr/doi/ https://doi.org/10.1002/14651858.CD008870.pub2/full
1. Akobeng AK, Zhang D, Gordon M, et al. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2016 Sep 28;9:CD003715.
1. Hart A, Ng SC, Watkins J et al. The use of 5-aminosalicylates in Crohn’s disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol. 2020;33:500–507. - PubMed - PMC
1. Ungaro RC, Limketkai BN, Jensen CB et al. Stopping Mesalamine Therapy in Patients With Crohn’s Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clin Gastroenterol Hepatol. 2020;18:1152-1160.e1. - DOI
1. Singh S, Kim J, Zhu W et al. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Alimentary Pharmacology & Therapeutics. 2020;52:481–491. - DOI